Fundraising Fox
Synlogic
OTC: SYBXCambridge, US · Founded 2014 · Delaware corporation · 19 employees on LinkedIn · 8 known investors
Find your way into Synlogic
Each arrow is one introduction. Sign up to fill in the first one.
189 people can intro you to Paul
Ask Samantha Truex to introduce you to Paul Miller
You →Samantha · together at Synlogic →Paul
Sign up to find every way you can get introduced to Synlogic
- Your email: who you already know at Synlogic, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Synlogic team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
Founders & leadership
MS
Michael SheahanExecutive
PM
Paul MillerChief Scientific Officer2014–2019Paul Miller is an Executive Officer at Synlogic, a company developing synthetic biology-based biotherapeutics using engineered living organisms. He has spent his career working in drug discovery and development, with experience in strategic planning, clinical development, and team leadership.
DG
DANIEL GEFFKENExecutive
Board
EM
AM
Ankit MahadeviaBoard director
PB
NL
Nick LeschlyBoard director
Investors · 8
Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M
How we know: Atlas Venture's portfolio page · a partner's Signal profile · Not right? Tell us
New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Edward Mathers · board
How we know: the S-1 prospectus · board seat on SEC Form D · Not right? Tell us
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$77M disclosed across 4 rounds · 2014–2017
▶$42MraisedMay 2017 · 16 investors · BiotechnologyRule 506(b)
▶$42MraisedMay 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul MillerExecutive Officer
- Peter BarrettDirector
- Chau KhuongDirector
- Aoife BrennanExecutive Officer
- Nick LeschlyDirector
- Lewis GeffenExecutive Officer
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Ed MathersDirector
- Todd ShegogExecutive Officer
- Offering amount
- $42M
- Amount sold
- $42M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$17.1MraisedFeb 2016 · 3 investors · BiotechnologyRule 506(b)
▶$17.1MraisedFeb 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ed MathersDirector
- Chau KhuongDirector
- Bharatt ChowriraExecutive Officer
- Ankit MahadeviaDirector
- Michael SheahanExecutive Officer
- Peter BarrettDirector
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Lewis GeffenExecutive Officer
- Offering amount
- $17.1M
- Amount sold
- $17.1M
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$13.9MraisedFeb 2016 · 2 investors · BiotechnologyRule 506(b)
▶$13.9MraisedFeb 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jose Carlos Gutierrez-RamosExecutive Officer, Director
- Ed MathersDirector
- Lewis GeffenExecutive Officer
- Bharatt ChowriraExecutive Officer
- Michael SheahanExecutive Officer
- Peter BarrettDirector
- Chau KhuongDirector
- Ankit MahadeviaDirector
- Offering amount
- $40.6M
- Amount sold
- $13.9M
- First sale
- Feb 2016
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$4MraisedJul 2014 · 2 investors · BiotechnologyRule 506(b)
▶$4MraisedJul 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- DANIEL GEFFKENExecutive Officer
- ED MATHERSDirector
- PETER BARRETTDirector
- ANKIT MAHADEVIAExecutive Officer, Director
- LEWIS GEFFENExecutive Officer
- Offering amount
- $29.4M
- Amount sold
- $4M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Synlogic went on to found or lead other companies.
Related companies · 5
AbiologicsAbiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
SentynlA biopharmaceutical company developing novel medicines for rare diseases, serving patients and caregivers from early detection through therapeutic intervention.
Senti BiosciencesSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Syneos HealthSyneos Health is a fully integrated biopharmaceutical solutions organization that provides clinical, medical affairs, and commercial services to help pharmaceutical companies accelerate market access and patient outcomes.
Companies working in the same space as Synlogic.
Frequently asked questions
- What does Synlogic do?
- Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
- Who are Synlogic's investors?
- Synlogic's investors include Atlas Venture, CLI Ventures, New Enterprise Associates (NEA), NSG Ventures, Pfizer Venture Investments, Sofinnova Ventures, Solasta Ventures, OrbiMed.
- How much funding has Synlogic raised?
- Synlogic has disclosed $77M raised across 4 rounds.
- Where is Synlogic headquartered?
- Synlogic is headquartered in Cambridge, US.